Patterns of antibodies in the blood could predict inflammatory bowel disease up to a decade before clinical diagnosis, according to research presented at United European Gastroenterology Week 2026 in Barcelona and published in the journal Gut. The findings offer a potential path toward earlier risk detection for Crohn’s disease and ulcerative colitis.
Tracking Immune Shifts a Decade Before IBD Diagnosis
Chronic conditions like Crohn’s disease and ulcerative colitis usually remain undetected until symptoms emerge and intestinal damage has already occurred. Researchers evaluated a total of 2,000 serum specimens gathered from 500 subjects, which comprised 200 individuals who subsequently developed Crohn’s disease, 200 who later developed ulcerative colitis, alongside 100 healthy controls matched for age and sex. Doctors from Mount Sinai and the Medical University of Vienna analyzed these blood samples taken from U.S. military personnel.
Researchers measured antibody reactivity against protein fragments from viruses, bacteria, food products, and the body’s own tissues. Participants who eventually developed inflammatory bowel disease showed that the immune system undergoes pathological changes years before clinical disease becomes apparent.
Distinct Antibody Patterns for Crohn’s Disease and Ulcerative Colitis
The study found clear differences in the immune signatures preceding Crohn’s disease and ulcerative colitis. Participants who developed Crohn’s disease showed elevated antibody responses against herpesviruses, such as the Epstein-Barr virus, and flagellin, particularly those who later developed complicated or ileal disease. In contrast, antibody responses against encapsulated bacteria declined as diagnosis approached. Patients with ulcerative colitis were found to have a different specific antibody profile, reacting to one of the body’s own proteins.
For too long we have only been able to treat inflammatory bowel disease once the damage is done, and for many people that is too late.
Dr. Arno Bourgonje, University Medical Centre Groningen and Icahn School of Medicine at Mount Sinai
Researchers investigated whether blocking autoantibodies against interleukin-10—an anti-inflammatory signal—might explain IBD in the wider population. They found that roughly 3.5% of adult IBD patients and about 2.2% of children with IBD showed blocking antibodies against IL-10, a response entirely absent in healthy individuals.
Machine Learning Models Predict IBD Severity Ten Years Early
Machine learning models successfully distinguished people who would develop IBD from healthy participants up to 10 years before diagnosis. Using these computational models, researchers successfully separated healthy individuals from those destined to develop Crohn’s disease or ulcerative colitis as early as ten years prior to their diagnosis. More importantly, the profiles differentiated individuals who later developed complicated Crohn’s disease from those with non-complicated disease up to a decade prior. This indicates that severe disease trajectories are not simply consequences of unchecked progression after diagnosis.
It is fascinating to see that diagnosis is associated with a distinct antibody profile years before the first clinical symptoms and is not simply the consequence of disease progression after diagnosis.
Arno R. Bourgonje, MD, PhD, postdoctoral fellow at the University Medical Center Groningen
Independent experts note that while the study offers important insights into the causes of Crohn’s disease and ulcerative colitis, the techniques remain very much a research tool not yet ready for routine clinical use. Patient advocacy groups emphasize that every new insight helps build a clearer understanding of how these conditions develop.
Next Steps for Validation and Clinical Translation
Researchers stress that the findings require confirmation in independent, more diverse, and prospectively followed populations. Future priorities include determining the added value of antibody signatures alongside genetic and clinical markers, developing a reproducible and affordable targeted assay, and demonstrating that early testing yields improved clinical outcomes. Readers concerned about chronic digestive symptoms should consult qualified healthcare professionals for appropriate medical evaluation, diagnosis, and management.
